Press coverage about Beyondspring (NASDAQ:BYSI) has been trending somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Beyondspring earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the company an impact score of 45.9863738693475 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Beyondspring (NASDAQ BYSI) opened at $30.04 on Thursday. The stock has a market capitalization of $744.29 and a PE ratio of -6.75. Beyondspring has a 12-month low of $16.55 and a 12-month high of $48.49.
Beyondspring (NASDAQ:BYSI) last posted its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.69) by $0.01. equities research analysts forecast that Beyondspring will post -4.41 EPS for the current year.
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.